ライフサイエンスコーパス: glucuronoxylomannan

1 in building the main capsule polysaccharide, glucuronoxylomannan.

2 ted with higher serum titers of cryptococcal glucuronoxylomannan.

3 mAb 2H1 binds C. neoformans glucuronoxylomannan.

4 or the major type-specific capsular antigen, glucuronoxylomannan.

5 survival, reducing CFU, and reducing tissue glucuronoxylomannan Ag. mAb administration was associate

6 tococcus neoformans capsular polysaccharides glucuronoxylomannan and galactoxylomannan (GalXM) elicit

7 de of two xylose-containing polysaccharides, glucuronoxylomannan and galactoxylomannan.

8 While glucuronoxylomannan-binding immunoglobulin G (GXM-IgG) l

9 Monoclonal antibodies to the capsular glucuronoxylomannan can modulate the infection in mice,

10 efficacy of mAbs to Cryptococcus neoformans glucuronoxylomannan depends on Ab isotype.

11 Capsular polysaccharide glucuronoxylomannan deposition, astrogliosis, and morpho

12 the MAb was not cross-reactive with purified glucuronoxylomannan derived from either serotypes A or D

13 1, one of a large family of mAbs against the glucuronoxylomannan fraction (GXM), is highly protective

14 n V region usage for Cryptococcus neoformans glucuronoxylomannan, glucuronoxylomannan peptide mimetic

15 sis of the two main capsule polysaccharides, glucuronoxylomannan (GXM) and galactoxylomannan (GalXM),

16 l for virulence and is composed primarily of glucuronoxylomannan (GXM) and galactoxylomannan (GalXM).

17 eactive with the cryptococcal polysaccharide glucuronoxylomannan (GXM) are present in sera from both

18 sma levels of immunoglobulins, C. neoformans glucuronoxylomannan (GXM) capsule-specific and laminarin

19 ine monoclonal antibodies (MAbs) against the glucuronoxylomannan (GXM) component of the C. neoformans

20 ith a glycoconjugate vaccine composed of the glucuronoxylomannan (GXM) component of the cryptococcal

21 ith a glycoconjugate vaccine composed of the glucuronoxylomannan (GXM) component of the cryptococcal

22 pertoire of human antibodies to cryptococcal glucuronoxylomannan (GXM) elicited by the investigationa

23 or (PAF) content in mice given C. neoformans glucuronoxylomannan (GXM) followed by specific Ab of IgG

24 o biological function of human antibodies to glucuronoxylomannan (GXM) from individuals immunized wit

25 ptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been rigorously investiga

26 ptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been shown to be protecti

27 to the C. neoformans capsular polysaccharide glucuronoxylomannan (GXM) have demonstrated that patient

28 response to Cryptococcus neoformans capsular glucuronoxylomannan (GXM) in BALB/c mice frequently expr

29 antibodies (Abs) to Cryptococcus neoformans glucuronoxylomannan (GXM) is dependent on Ab fine specif

30 Cryptococcus neoformans capsular glucuronoxylomannan (GXM) is shed during cryptococcosis

31 Most mAbs to the capsular polysaccharide glucuronoxylomannan (GXM) of Cryptococcus neoformans are

32 Specifically, the glucuronoxylomannan (GXM) of the WR polysaccharide diffe

33 GXM10-Ac(3) was designed as an extension of glucuronoxylomannan (GXM) polysaccharide motif (M2) whic

34 IgA to the Cryptococcus neoformans capsular glucuronoxylomannan (GXM) promote complement-independent

35 epitope in Cryptococcus neoformans capsular glucuronoxylomannan (GXM) that can elicit protective ant

36 l constituents of native and de-O-acetylated glucuronoxylomannan (GXM) was determined by one-dimensio

37 Significantly less glucuronoxylomannan (GXM) was released by C. neoformans

38 ypes of cryptococcal capsular polysaccharide glucuronoxylomannan (GXM) was studied, followed by an as

39 Cryptococcal glucuronoxylomannan (GXM), but not galactoxylomannan or

40 or the major capsular polysaccharide, termed glucuronoxylomannan (GXM), can markedly suppress the abi

41 mAbs that recognize two epitopes of capsular glucuronoxylomannan (GXM), defined by the IgG1 mAbs 2H1

42 with cryptococcal capsular polysaccharide, a glucuronoxylomannan (GXM), exhibit increased survival ti

43 of CneF and its individual components, i.e., glucuronoxylomannan (GXM), galactoxylomannan (GalXM), an

44 rmine if cryptococcal polysaccharides, i.e., glucuronoxylomannan (GXM), galactoxylomannan, and mannop

45 ptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM), in mice that produce human an

46 r polysaccharide of Cryptococcus neoformans, glucuronoxylomannan (GXM), is recognized by Toll-like re

47 immunoglobulin M (IgM) and IgG responses to glucuronoxylomannan (GXM), lack of IgE regulation during

48 2H1, which binds to Cryptococcus neoformans glucuronoxylomannan (GXM), on pulmonary infection in imm

49 of the cryptococcal capsular polysaccharide glucuronoxylomannan (GXM), the key C. neoformans virulen

50 Monoclonal antibodies (MAbs) reactive with glucuronoxylomannan (GXM), the major capsular polysaccha

51 the host response to Cryptococcus neoformans glucuronoxylomannan (GXM), the major capsular polysaccha

52 urine macrophages treated with extracellular glucuronoxylomannan (GXM), the major Cn capsular polysac

53 Glucuronoxylomannan (GXM), the major component of the ca

54 ed that the 18B7 monoclonal antibody against glucuronoxylomannan (GXM), the major component of the Cr

55 CPS or its major component, glucuronoxylomannan (GXM), was administered to mice, and

56 Cryptococcal capsular glucuronoxylomannan (GXM)- and naturally occurring beta-

57 aride capsule that consists predominantly of glucuronoxylomannan (GXM).

58 city differences for Cryptococcus neoformans glucuronoxylomannan (GXM).

59 charide capsule whose primary constituent is glucuronoxylomannan (GXM).

60 levels of the major capsular polysaccharide, glucuronoxylomannan (GXM).

61 bodies (MAbs) to the capsular polysaccharide glucuronoxylomannan (GXM).

62 olysaccharide capsule comprised primarily of glucuronoxylomannan (GXM).

63 Cryptococcus neoformans glucuronoxylomannans (GXM) are capsular polysaccharides

64 Purified capsular polysaccharide (glucuronoxylomannan [GXM]) also stimulated the PC to sec

65 ropriate for a role in the synthesis of this glucuronoxylomannan is active in cryptococcal membranes.

66 that the main fungal capsule polysaccharide glucuronoxylomannan is responsible for these alterations

67 ed the conservation of previously identified glucuronoxylomannan motifs only in the sonicated CPS.

68 Cryptococcus neoformans glucuronoxylomannan, glucuronoxylomannan peptide mimetics, and anti-Id mAbs.

69 Immunostaining for glucuronoxylomannan showed isolated cryptococci inside t

70 t have specificity appropriate for a role in glucuronoxylomannan synthesis, it may participate in pro

71 cryptococcal capsular polysaccharide vaccine glucuronoxylomannan-tetanus toxoid (GXM-TT) have been sh

72 These results indicate that glucuronoxylomannan, the major cryptococcal capsule poly

73 sion of antibodies to C. neoformans capsular glucuronoxylomannan were analyzed by ELISA.

74 saccharide capsule composed predominantly of glucuronoxylomannan, which constitutes approximately 90%